4.7 Review

Coronary Artery Disease in Patients ≥80 Years of Age

期刊

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 71, 期 18, 页码 2015-2040

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2017.12.068

关键词

coronary artery disease; geriatric cardiology; octogenarians

资金

  1. American Medical Association Foundation
  2. Gilead Sciences
  3. Sanofi
  4. GlaxoSmithKline
  5. AstraZeneca
  6. Bayer
  7. Bristol-Myers Squibb
  8. Boehringer Ingelheim
  9. Daiichi-Sankyo
  10. Janssen Pharmaceuticals
  11. Novartis Pharmaceutical Company
  12. Medtronic Foundation
  13. Pfizer
  14. U.S. Food and Drug Administration
  15. National Institutes of Health
  16. Boston Scientific
  17. Lilly
  18. Medtronic
  19. Merck

向作者/读者索取更多资源

Coronary artery disease (CAD) is a major cause of morbidity and mortality in patients >= 80 years of age. Nonetheless, older patients have typically been under-represented in cardiovascular clinical trials. Understanding the pathophysiology, epidemiology, and optimal means of diagnosis and treatment of CAD in older adults is crucial to improving outcomes in this high-risk population. A patient-centered approach, taking into account health status, functional ability and frailty, cognitive skills, and patient preferences is essential when caring for older adults with CAD. The present systematic review focuses on the current knowledge base, gaps in understanding, and directions for future investigation pertaining to CAD in patients >= 80years of age. (C) 2018 by the American College of Cardiology Foundation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据